BMJ Best Practice

参考文献

关键文献

Roberts CG, Ladenson PW. Hypothyroidism. Lancet. 2004;363:793-803.

Persani L. Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab. 2012;97:3068-3078.

Baskin HJ, Cobin RH, Duick DS, et al. AACE medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457-469.

Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med. 2000;160:1573-1575.

Clarke N, Kabadi UM. Optimizing treatment of hypothyroidism. Treat Endocrinol. 2004;3:217-221.

Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24:1670-1751.

参考文章

1.  Mulder JE. Thyroid disease in women. Med Clin North Am. 1998;82:103.

2.  Roberts CG, Ladenson PW. Hypothyroidism. Lancet. 2004;363:793-803.

3.  Zarnegar R, Brunaud L, Clark OH. Multiple endocrine neoplasia type I. Curr Treat Options Oncol. 2002;3:335-348.

4.  Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol. 1994;41:359-364.

5.  Bates AS, VaHoff W, Jones PJ, et al. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab. 1996;81:1169.

6.  Mathioudakis N, Thapa S, Wand GS, et al. ACTH-secreting pituitary microadenomas are associated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clin Endocrinol (Oxf). 2012;77:871-876.

7.  Stuart CA, Neelon FA, Lebovitz HE. Hypothalamic insufficiency: the cause of hypopituitarism in sarcoidosis. Ann Intern Med. 1978;88:589-594.

8.  Charbonnel B, Chupin M, Le Grand A, et al. Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. Acta Endocrinol. 1981;98:178-183.

9.  Modan-Moses D, Weintraub M, Meyerovitch J, et al. Hypopituitarism in Langerhans cell histiocytosis: seven cases and literature review. J Endocrinol Invest. 2001;24:612-617.

10.  Benvenga S, Campenni A, Ruggeri RM, et al. Clinical review 113: Hypopituitarism secondary to head trauma. J Clin Endocrinol Metab. 2000;85:1353-1361.

11.  Randeva HS, Schoebel J, Byrne J, et al. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf). 1999;51:181-188.

12.  Barkan AL. Pituitary atrophy in patients with Sheehan's syndrome. Am J Med Sci. 1989;298:38-40.

13.  Kokshoorn NE, Wassenaar MJ, Biermasz NR, et al. Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. Eur J Endocrinol. 2010;162:11-18.

14.  Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med. 1986;81:457.

15.  Collu R, Tang J, Castagne J, et al. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab. 1997;82:1361.

16.  Hayashizaki Y, Hiraoka Y, Tatsumi K, et al. Deoxyribonucleic acid analyses of five families with familial inherited thyroid stimulating hormone deficiency. J Clin Endocrinol Metab. 1990;71:792.

17.  Sun Y, Bak B, Schoenmakers N, et al. Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat Genet. 2012;44:1375-1381.

18.  Tajima T, Nakamura A, Ishizu K. A novel mutation of IGSF1 in a Japanese patient of congenital central hypothyroidism without macroorchidism [Rapid Communication]. Endocr J. 2013;60:245-249.

19.  García M, Fernández A, Moreno JC. Central hypothyroidism in children. Endocr Dev. 2014;26:79-107.

20.  Tajima T, Nakamura A, Morikawa S, et al. Neonatal screening and a new cause of congenital central hypothyroidism. Ann Pediatr Endocrinol Metab. 2014;19:117-121.

21.  Schoenmakers N, Alatzoglou KS, Chatterjee VK, et al. Recent advances in central congenital hypothyroidism. J Endocrinol. 2015;227:51-71.

22.  Persani L, Bonomi M. The multiple genetic causes of central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2017;31:255-263.

23.  Thodou E, Asa SL, Kontogeorgos G, et al. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab. 1995;80:2302-2311.

24.  Magner JA. Thyroid-stimulating hormone: biosynthesis, cell biology, and bioactivity. Endocr Rev. 1990;11:354-385.

25.  Jackson, IM. Thyrotropin-releasing hormone. N Engl J Med. 1982;306:145.

26.  Dyess EM, Segerson TP, Liposits Z, et al. Triiodothyronine exerts direct cell-specific regulation of thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus. Endocrinology. 1988;123:2291-2297.

27.  Dacou-Voutetakis C, Feltquate DM, Drakopoulou M, et al. Familial hypothyroidism caused by a nonsense mutation in the thyroid-stimulating hormone beta-subunit gene. Am J Hum Genet. 1990;46:988.

28.  Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Invest. 2002:25:650-662.

29.  Darzy KH, Shalet SM. Hypopituitarism after cranial irradiation. J Endocrinol Invest. 2005;28(suppl 5):78-87.

30.  Bhandare N, Kennedy L, Malyapa RS, et al. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2007;68:1131-1139.

31.  Powner DJ, Boccalandro C, Alp MS, et al. Endocrine failure after traumatic brain injury in adults. Neurocrit Care. 2006;5:61-70.

32.  Dokmetas HS, Kilicli F, Korkmaz S, et al. Characteristic features of 20 patients with Sheehan’s syndrome. Gynaecol Endocrinol. 2006;25:279-283.

33.  Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocr Rev. 2005;26:599-614.

34.  Faglia G, Bitensky L, Pinchera A, et al. Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biologic activity of immunoreactive thyrotropin. J Clin Endocrinol Metab. 1979;48:989-998.

35.  Persani L. Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab. 2012;97:3068-3078.

36.  Fitzpatrick M, Tartaglino LM, Hollander MD, et al. Imaging of sellar and parasellar pathology. Radiol Clin North Am. 1999;37:101-121.

37.  Stadnik T, Spruyt D, van Binst A, et al. Pituitary microadenomas: diagnosis with dynamic serial CT, conventional CT and T1-weighted MR imaging before and after injection of gadolinium. Eur J Radiol. 1994;18:191-198.

38.  Gao R, Tanaka T, Inagawa S, et al. Dynamic gadolinium-enhanced MR imaging of pituitary adenomas: usefulness of sequential sagittal and coronal plane images. Eur J Radiol. 2001;39:139-146.

39.  Anand VT, Mann SB, Dash RJ, et al. Auditory investigations in hypothyroidism. Acta Otolaryngol. 1989;108:83-87.

40.  Canaris GJ, Steiner JF, Ridgway EC. Do traditional symptoms of hypothyroidism correlate with biochemical disease? J Gen Intern Med. 1997;12:544-550.

41.  Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169:575-581.

42.  Rennert J, Doerfler A. Imaging of sellar and parasellar lesions. Clin Neurol Neurosurg. 2007;109:111-124.

43.  Baskin HJ, Cobin RH, Duick DS, et al. AACE medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457-469.

44.  Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol. 2003;2:23-32.

45.  Schneider H, Aimoretti G, Kreitschmann-Andermahr M, et al. Hypopituitarism. Lancet. 2007;369:1461-1470.

46.  Hertzman PA. Criteria for the definition of the eosinophilia-myalgia syndrome. J Rheumatol. 1996;46:7-12.

47.  Varga J, Kahari VM. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. Curr Opin Rheumatol. 1997;9:562-570.

48.  Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med. 2000;160:1573-1575.

49.  Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18:988-1028.

50.  LeFevre ML; US Preventive Services Task Force. Screening for thyroid dysfunction: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015;162:641-650.

51.  Rose SR, Brown RS, Foley T, et al; American Academy of Pediatrics. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics. 2006;117:2290-2303.

52.  Grunenwald S, Caron P. Central hypothyroidism in adults: better understanding for better care. Pituitary. 2015;18:169-175.

53.  Clarke N, Kabadi UM. Optimizing treatment of hypothyroidism. Treat Endocrinol. 2004;3:217-221.

54.  Beck-Peccoz P. Treatment of central hypothyroidism. Clin Endocrinol (Oxf). 2011;74:671-672.

55.  Yamada M, Mori M. Mechanisms related to the pathophysiology and management of central hypothyroidism. Nat Clin Pract Endocrinol Metab. 2008;4:683-694.

56.  Lania A, Persani L, Beck-Peccoz P. Central hypothyroidism. Pituitary. 2008;11:181-186.

57.  Alexopoulou O, Beguin C, De Nayer P, et al. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol. 2004;150:1-8.

58.  Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014;35:433-512.

59.  Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24:1670-1751.

60.  Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273-288.

61.  Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinology (Oxf). 2006;65:265-273.

62.  Buchfelder M, Schlaffer S. Surgical treatment of pituitary tumours. Best Pract Res Clin Endocrinol Metab. 2009;23:677-692.

63.  Melmed S, Colao A, Barkan A, et al; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509-1517.

64.  Minniti G, Gilbert DC, Brada M. Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord. 2009;10:135-144.

65.  American Association of Clinical Endocrinologists. AACE, TES, and ATA joint position statement on the use and interchangeability of thyroxine products. 2004. https://www.aace.com/ (last accessed 18 September 2017).

66.  Mackley HB, Reddy CA, Lee SH, et al. Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience. Int J Radiat Oncol. 2007;67:232-239.

67.  Laws ER, Sheehan JP, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol. 2004;69;257-272.

68.  Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol. 2001;54:139-150.

69.  Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005;90:5627-5631.

70.  Schneider R, Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabetes. 2003;111:455-470.

使用此内容应接受我们的免责声明